NCT02266615 Biobank Clinical Genetics Maastricht (KG01)
| NCT ID | NCT02266615 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht University Medical Center |
| Condition | Genetic Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,600 participants |
| Start Date | 2014-09 |
| Primary Completion | 2024-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,600 participants in total. It began in 2014-09 with a primary completion date of 2024-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Collection of coded biomaterial and clinical data with patients consent for future research.
Eligibility Criteria
Inclusion Criteria: * New patients visiting the out patient clinic of the department of Clinical Genetics of the Maastricht University Medical Hospital * Withdrawal of body material for genetic diagnostics. Exclusion Criteria: * Patient does not understand the Dutch language.
Contact & Investigator
W. van Zelst-Stams, MD, PhD
STUDY DIRECTOR
Head of department
Frequently Asked Questions
Who can join the NCT02266615 clinical trial?
This trial is open to participants of all sexes, studying Genetic Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02266615 currently recruiting?
Yes, NCT02266615 is actively recruiting participants. Contact the research team at ingrid.krapels@mumc.nl for enrollment information.
Where is the NCT02266615 trial being conducted?
This trial is being conducted at Maastricht, Netherlands.
Who is sponsoring the NCT02266615 clinical trial?
NCT02266615 is sponsored by Maastricht University Medical Center. The principal investigator is W. van Zelst-Stams, MD, PhD at Head of department. The trial plans to enroll 3,600 participants.